^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
KUR-501
i
Other names: KUR-501, CMD-501, CAR-NKT therapy, CAR.GD2-IL-15 NKTs, Chimeric antigen receptors natural killer T-cells (CAR-NKT) therapy, GINAKIT cells, GD2-CAR, GD2-CAR NKT cells, CAR-modified NKT-cell therapy
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Athenex, Baylor College of Medicine, Texas Children’s Hospital
Drug class:
GD2 ganglioside inhibitor
Related drugs:
9d
GINAKIT2: GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children with Neuroblastoma (clinicaltrials.gov)
P1, N=54, Recruiting, Baylor College of Medicine | N=36 --> 54
Enrollment change
|
KUR-501
over1year
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. (PubMed, Nat Med)
No dose-limiting toxicities occurred; one patient experienced grade 2 cytokine release syndrome that was resolved by tocilizumab. Additionally, their anti-tumor activity may be enhanced by targeting BTG1. ClinicalTrials.gov registration: NCT03294954 .
P1 data • Journal
|
IL15 (Interleukin 15)
|
Actemra IV (tocilizumab) • KUR-501
Share via
